利妥昔单抗治疗儿童及青少年成熟B细胞非霍奇金淋巴瘤疗效及安全性的Meta分析

doi:10.7499/j.issn.1008-8830.2208015

摘要
图/表
参考文献(38)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (1296 KB) [HTML]
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的通过Meta分析探讨在儿童及青少年成熟B细胞非霍奇金淋巴瘤治疗中应用利妥昔单抗联合化疗的疗效与安全性，为更加合理地应用利妥昔单抗提供理论依据。方法检索PubMed、Embase、Cochrane Library、ClinicalTrials.gov、Web of Science、中国知网、万方、维普数据库的文献，共筛选出从建库至2022年6月公开发表的利妥昔单抗治疗儿童及青少年成熟B细胞非霍奇金淋巴瘤的10篇文献，共计886例患儿。以3年无事件生存率、3年总生存率、完全缓解率、病死率和不良反应发生率作为结局指标，采用RevMan 5.4软件进行Meta分析、亚组分析、敏感性分析和发表偏倚分析。结果与单纯化疗组相比，利妥昔单抗联合化疗组3年无事件生存率显著提高（HR=0.38，95%CI：0.25~0.59，P<0.001），3年总生存率显著提高（HR=0.29，95%CI：0.14~0.61，P=0.001），完全缓解率显著提高（OR=3.72，95%CI：1.89~7.33，P<0.001），病死率显著降低（OR=0.31，95%CI：0.17~0.57，P<0.001）。而两组的不良反应发生率差异无统计学意义（OR=1.28，95%CI：0.85~1.92，P=0.24）。结论在儿童及青少年成熟B细胞非霍奇金淋巴瘤治疗方案中添加利妥昔单抗可带来明显的生存益处，且不会增加不良反应的发生。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李碧云
	韩亚辉
	殷楚云
	杜伟闯
	李远方
	王颖超

关键词 ：非霍奇金淋巴瘤, 利妥昔单抗, 化疗, Meta分析, 儿童, 青少年

Abstract：Objective To study the efficacy and safety of rituximab combined with chemotherapy in the treatment of children and adolescents with mature B-cell non-Hodgkin's lymphoma (B-NHL) through a Meta analysis. Methods The databases including PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, Web of Science, China National Knowledge Infrastructure, Wanfang Data, and Weipu were searched to obtain 10 articles on rituximab in the treatment of mature B-NHL in children and adolescents published up to June 2022, with 886 children in total. With 3-year event-free survival (EFS) rate, 3-year overall survival (OS) rate, complete remission rate, mortality rate, and incidence rate of adverse reactions as outcome measures, RevMan 5.4 software was used for Meta analysis, subgroup analysis, sensitivity analysis, and publication bias analysis. Results The rituximab+chemotherapy group showed significant increases in the 3-year EFS rate (HR=0.38, 95%CI: 0.25-0.59, P<0.001), 3-year OS rate (HR=0.29, 95%CI: 0.14-0.61, P=0.001), and complete remission rate (OR=3.72, 95%CI: 1.89-7.33, P<0.001) as well as a significant reduction in the mortality rate (OR=0.31, 95%CI: 0.17-0.57, P<0.001), as compared with the chemotherapy group without rituximab. There was no significant difference in the incidence rate of adverse reactions between the two groups (OR=1.28, 95%CI: 0.85-1.92, P=0.24). Conclusions The addition of rituximab to the treatment regimen for children and adolescents with mature B-cell non-Hodgkin's lymphoma can bring significant survival benefits without increasing the incidence of adverse reactions.

Key words： Non-Hodgkin's lymphoma Rituximab Chemotherapy Meta analysis Child Adolescent

收稿日期: 2022-08-04

通讯作者: 王颖超，男，主任医师。Email：13838520369@163.com。 E-mail: 13838520369@163.com

作者简介: 李碧云，女，硕士研究生；

引用本文:

李碧云,韩亚辉,殷楚云等. 利妥昔单抗治疗儿童及青少年成熟B细胞非霍奇金淋巴瘤疗效及安全性的Meta分析[J]. 中国当代儿科杂志, 2023, 25(1): 51-59.

LI Bi-Yun,HAN Ya-Hui,YIN Chu-Yun et al. Efficacy and safety of rituximab in children and adolescents with mature B-cell non-Hodgkin's lymphoma: a Meta analysis[J]. CJCP, 2023, 25(1): 51-59.

链接本文:

http://www.zgddek.com/CN/10.7499/j.issn.1008-8830.2208015 或 http://www.zgddek.com/CN/Y2023/V25/I1/51

	Harker-Murray PD, Pommert L, Barth MJ. Novel therapies potentially available for pediatric B-cell non-Hodgkin lymphoma[J]. J Natl Compr Canc Netw, 2020, 18(8): 1125-1134. PMID: 32755987. DOI: 10.6004/jnccn.2020.7608.
	Egan G, Goldman S, Alexander S. Mature B-NHL in children, adolescents and young adults: current therapeutic approach and emerging treatment strategies[J]. Br J Haematol, 2019, 185(6): 1071-1085. PMID: 30613948. DOI: 10.1111/bjh.15734.
	Salles G, Barrett M, Foà R, et al. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience[J]. Adv Ther, 2017, 34(10): 2232-2273. PMID: 28983798. PMCID: PMC5656728. DOI: 10.1007/s12325-017-0612-x.
	Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study[J]. Lancet Oncol, 2017, 18(8): 1076-1088. PMID: 28668386. DOI: 10.1016/S1470-2045(17)30444-8.
	Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. PMID: 26980727. PMCID: PMC4874220. DOI: 10.1182/blood-2016-01-643569.
	Moleti ML, Testi AM, Foà R. Treatment of relapsed/refractory paediatric aggressive B-cell non-Hodgkin lymphoma[J]. Br J Haematol, 2020, 189(5): 826-843. PMID: 32141616. DOI: 10.1111/bjh.16461.
	Minard-Colin V, Aupérin A, Pillon M, et al. Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children[J]. N Engl J Med, 2020, 382(23): 2207-2219. PMID: 32492302. PMCID: PMC7720281. DOI: 10.1056/NEJMoa1915315.
	张梦, 金玲, 杨菁, 等. 儿童伯基特淋巴瘤186例临床特征及疗效分析[J]. 中华儿科杂志, 2018, 56(8): 605-610. PMID: 30078243. DOI: 10.3760/cma.j.issn.0578-1310.2018.08.010.
	Rigaud C, Auperin A, Jourdain A, et al. Outcome of relapse in children and adolescents with B-cell non-Hodgkin lymphoma and mature acute leukemia: a report from the French LMB study[J]. Pediatr Blood Cancer, 2019, 66(9): e27873. PMID: 31207026. DOI: 10.1002/pbc.27873.
	Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3): 83-87. PMID: 21171509.
	11 周支瑞, 张天嵩, 李博, 等. 生存曲线中Meta分析适宜数据的提取与转换[J]. 中国循证心血管医学杂志, 2014, 6(3): 243-247. DOI: 10.3969/j.1674-4055.2014.03.02.
	Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis[J]. Trials, 2007, 8: 16. PMID: 17555582. PMCID: PMC1920534. DOI: 10.1186/1745-6215-8-16.
	13 Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions: version 5.1.0[EB/OL]. (2011-03-20)[2020-10-06].
	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010, 25(9): 603-605. PMID: 20652370. DOI: 10.1007/s10654-010-9491-z.
	Dourthe ME, Phulpin A, Auperin A, et al. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study[J]. Haematologica, 2022, 107(9): 2173-2182. PMID: 35236054. PMCID: PMC9425314. DOI: 10.3324/haematol.2021.280257.
	Fu Y, Wang H, Zhai X, et al. Improved outcome of newly diagnosed childhood mature B-cell lymphoma/leukemia with high tumor burden treated with BFM95-based protocol combining rituximab: a report from Shanghai, China[J]. J Pediatr Hematol Oncol, 2019, 41(3): 170-174. PMID: 30664102. DOI: 10.1097/MPH.0000000000001419.
	Huang S, Jin L, Yang J, et al. Treatment outcome in children with central nervous system-positive Burkitt lymphoma using only intrathecal and systemic chemotherapy combined with rituximab[J]. Chin Med J (Engl), 2021, 134(11): 1329-1334. PMID: 33734131. PMCID: PMC8183724. DOI: 10.1097/CM9.0000000000001386.
	Zhen Z, Zhu J, Wang J, et al. Rituximab is highly effective in children and adolescents with Burkitt lymphoma in risk groups R2 to R4[J]. Pediatr Hematol Oncol, 2020, 37(6): 489-499. PMID: 32364412. DOI: 10.1080/08880018.2020.1759741.
	19 李红, 邵静波, 杨静薇, 等. 儿童Burkitt淋巴瘤远期疗效分析[J]. 中国小儿血液与肿瘤杂志, 2021, 26(5): 278-284. DOI: 10.3969/j.issn.1673-5323.2021.05.005.
	李永新, 尹青松, 艾昊, 等. 利妥昔单抗联合改良NHL-BFM-90方案对儿童及青少年伯基特淋巴瘤的远期疗效[J]. 中华医学杂志, 2019, 99(8): 605-610. PMID: 30818930. DOI: 10.3760/cma.j.issn.0376-2491.2019.08.008.
	王颖超, 杜伟闯, 殷楚云, 等. 儿童伯基特淋巴瘤62例临床特征及预后分析[J]. 中国当代儿科杂志, 2022, 24(5): 561-565. PMID: 35644197. PMCID: PMC9154366. DOI: 10.7499/j.issn.1008-8830.2111064.
	张梦, 金玲, 杨菁, 等. 改良LMB 89 C组方案治疗儿童高危伯基特淋巴瘤172例临床分析[J]. 中华血液学杂志, 2019, 40(8): 633-638. PMID: 31495128. PMCID: PMC7342876. DOI: 10.3760/cma.j.issn.0253-2727.2019.08.002.
	23 周令, 李战华, 李运玲. 利妥昔单抗对儿童高分期成熟B细胞非霍奇金淋巴瘤的疗效研究[J]. 实用癌症杂志, 2022, 37(1): 146-149. DOI: 10.3969/j.issn.1001-5930.2022.01.043.
	Barth MJ, Minard-Colin V. Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma[J]. Br J Haematol, 2019, 185(6): 1111-1124. PMID: 30701541. DOI: 10.1111/bjh.15783.
	Giulino-Roth L, Goldman S. Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children[J]. Br J Haematol, 2016, 173(4): 531-544. PMID: 26996160. DOI: 10.1111/bjh.13969.
	Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa[J]. Blood, 2018, 132(3): 254-263. PMID: 29769263. PMCID: PMC6053950. DOI: 10.1182/blood-2018-04-844472.
	Cairo MS, Beishuizen A. Childhood, adolescent and young adult non-Hodgkin lymphoma: current perspectives[J]. Br J Haematol, 2019, 185(6): 1021-1042. PMID: 30729513. PMCID: PMC6897376. DOI: 10.1111/bjh.15764.
	Thacker N, Bakhshi S, Chinnaswamy G, et al. Management of non-Hodgkin lymphoma: ICMR consensus document[J]. Indian J Pediatr, 2017, 84(5): 382-392. PMID: 28378140. DOI: 10.1007/s12098-017-2318-0.
	中华医学会儿科学分会血液学组, 中国抗癌协会儿科专业委员会, 《中华儿科杂志》编辑委员会. 儿童非霍奇金淋巴瘤诊疗建议[J]. 中华儿科杂志, 2011, 49(3): 186-192. PMID: 21575366. DOI: 10.3760/cma.j.issn.0578-1310.2011.03.006.
	Oosten LEM, Chamuleau MED, Thielen FW, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens[J]. Ann Hematol, 2018, 97(2): 255-266. PMID: 29209924. PMCID: PMC5754407. DOI: 10.1007/s00277-017-3167-7.
	Cairo M, Auperin A, Perkins SL, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: a report from the FAB/LMB 96 study group[J]. Br J Haematol, 2018, 182(6): 859-869. PMID: 29984828. PMCID: PMC6128751. DOI: 10.1111/bjh.15491.
	Maschan A, Myakova N, Aleinikova O, et al. Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M[J]. Br J Haematol, 2019, 186(3): 477-483. PMID: 31069789. DOI: 10.1111/bjh.15944.
	McAtee CL, Lubega J, Underbrink K, et al. Association of rituximab use with adverse events in children, adolescents, and young adults[J]. JAMA Netw Open, 2021, 4(2): e2036321. PMID: 33533931. PMCID: PMC7859842. DOI: 10.1001/jamanetworkopen.2020.36321.
	Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors[J]. Expert Rev Clin Immunol, 2019, 15(4): 383-389. PMID: 30580638. DOI: 10.1080/1744666X.2019.1562905.
	Srinivasan S, Roy Moulik N, Kc A, et al. Increased toxicities in children with Burkitt lymphoma treated with rituximab: experience from a tertiary cancer center in India[J]. Pediatr Blood Cancer, 2020, 67(11): e28682. PMID: 32865865. DOI: 10.1002/pbc.28682.
	36 FDA. FDA approves rituximab plus chemotherapy for pediatric cancer indications[EB/OL]. (2021-12-03)[2022-08-02]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-rituximab-plus-chemotherapy-pediatric-cancer-indications.
	中华医学会儿科学分会肿瘤学组, 中华医学会儿科学分会血液学组, 中国抗癌协会小儿肿瘤专业委员会,等. 儿童和青少年侵袭性成熟B细胞非霍奇金淋巴瘤诊疗专家共识[J]. 中华儿科杂志, 2020, 58(10): 790-795. PMID: 32987456. DOI: 10.3760/cma.j.cn112140-20200723-00745.
	Hayden PJ, Roddie C, Bader P, et al. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)[J]. Ann Oncol, 2022, 33(3): 259-275. PMID: 34923107. DOI: 10.1016/j.annonc.2021.12.003.